Jeremy Curnock Cook's guest appearances

Jeremy Curnock Cook

Australian Investors Podcast

On the Couch

OwlTail

Michelle Miller

Gary Phillips

In this 'On the Couch' special, Henry Jennings sits down with two small-cap biotechs and one fund manager to discuss what makes a successful biotech, and how to invest successfully in the cutting edge of medical science and drug treatments.Dr Michelle Miller, Managing Director at Biotron Ltd - Market Cap $23.5mOver 25 years in the biotech industry with extensive experience in commercial drug development.Since 2002 has been Chief Executive Officer at Biotron.BiotronDeveloping lead compound BIT225 for the treatment of HIV-1 and Hepatitis C. Two fully recruited Phase 2 HIV-1 trials underway in Sydney and Thailand, results expected mid-2023. Added a COVID-19 sub-study to one of its HIV-1 trials, with any participant of the trial being infected with SARS-CoV-2 being included. Results also expected mid-2023.Gary Phillips, Chief Executive Officer at Pharmaxis - Market Cap $38mJoined Pharmaxis in 2003 and was Commercial Director and Chief Operating Officer before being appointed Chief Executive Officer in 2013.PharmaxisDeveloping drugs for inflammatory and fibrotic diseases with a focus on bone marrow cancer myelofibrosis. 5 trials underway with multiple near-term value opportunities. PXS-5505 for myelofibrosis is in Phase 2 with a data readout expected mid-23. Also developing PXS-6302 as a topical skin scarring treatment, led by renowned burns specialist Professor Fiona Wood.Jeremy Curnock CookStarted out in the sector in 1973 founding a biotech company. Over his career successfully managed in excess of US$1b in equity investments.Founder and Managing Director of BioScience Managers, Non-Executive Director of AVITA Medical.BioScience ManagersAn international healthcare investment firm that invests in innovative science and technology. BioScience Managers was created in 2001 and established its Australian base in 2003, making it the oldest specialist biotech fund in Australia.Currently has A$250m funds under management.Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast.Why not sign up for a free trial? Get access to expert insights and research and become a better investor.

In this 'On the Couch' special, Henry Jennings sits down with two small-cap biotechs and one fund manager to discuss what makes a successful biotech, and how to invest successfully in the cutting edge of medical science and drug treatments. Dr Michelle Miller, Managing Director at Biotron Ltd - Market Cap $23.5m<ul><li>Over 25 years in the biotech industry with extensive experience in commercial drug development.</li><li>Since 2002 has been Chief Executive Officer at Biotron.</li></ul>BiotronDeveloping lead compound BIT225 for the treatment of HIV-1 and Hepatitis C. Two fully recruited Phase 2 HIV-1 trials underway in Sydney and Thailand, results expected mid-2023. Added a COVID-19 sub-study to one of its HIV-1 trials, with any participant of the trial being infected with SARS-CoV-2 being included. Results also expected mid-2023. Gary Phillips, Chief Executive Officer at Pharmaxis - Market Cap $38m<ul><li>Joined Pharmaxis in 2003 and was Commercial Director and Chief Operating Officer before being appointed Chief Executive Officer in 2013.</li></ul>PharmaxisDeveloping drugs for inflammatory and fibrotic diseases with a focus on bone marrow cancer myelofibrosis. 5 trials underway with multiple near-term value opportunities. PXS-5505 for myelofibrosis is in Phase 2 with a data readout expected mid-23. Also developing PXS-6302 as a topical skin scarring treatment, led by renowned burns specialist Professor Fiona Wood. Jeremy Curnock Cook<ul><li>Started out in the sector in 1973 founding a biotech company. </li><li>Over his career successfully managed in excess of US$1b in equity investments.</li><li>Founder and Managing Director of BioScience Managers, Non-Executive Director of AVITA Medical.</li></ul>BioScience ManagersAn international healthcare investment firm that invests in innovative science and technology. BioScience Managers was created in 2001 and established its Australian base in 2003, making it the oldest specialist biotech fund in Australia. Currently has A$250m funds under management. Disclaimer: This is general advice only and you should consult your financial adviser regarding any of the thoughts, ideas or insights in this podcast. Why not <a href="https://marcustoday.com.au/trial-sign-up/" rel="nofollow" target="_blank">sign up for a free trial</a>? Get access to expert insights and research and become a better investor.

On the Couch | Biotech Special with Michelle Miller (BIT), Gary Phillips (PXS) and Jeremy Curnock Cook (BioScience Managers)

Megan Baldwin

Jeremy Curnock Cook is the Managing Director and founder of BioScience Managers, a funds management business specialising in biotechnology investments in Australia and globally. Jeremy joins Owen Rask on The Australian Investors Podcast, alongside Dr Megan Baldwin of Opthea Ltd (ASX: OPT). Dr Baldwin is one of Australia's most experienced biotechnology CEOs and holds a PhD in Medicine.Together, Owen, Megan and Jeremy dive deep into what's included in clinical trials, investing in early, mid and late-stage biotechnology and more.Owen's full investor curriculumTake Owen’s brand new Value Investor Program, which gives you all the tools and knowledge you need to invest successfully in companies, including valuation spreadsheets, investing checklists and ASX company case studies. Alternatively, why not take Owen’s FREE investor bootcamp: bit.ly/rask-analystJ.P. Morgan Asset ManagementIf you want to thank us for putting this show together, please give The Australian Investors Podcast a 5-star review on Apple Podcasts or Spotify - it’s a 5-second task that really helps support the show (and puts a big smile on Owen's face).The Australian Investors Podcast series is proudly supported by J.P. Morgan Asset Management. With over $3.4tn in assets under management globally, J.P. Morgan ETFs push the boundaries of ETF investing to help build stronger, diversified active portfolios. This information is generic in nature and does not constitute as offer or personal financial advice. Investors should seek professional advice, refer to further details, relevant Product Disclosure Statement and Target Market Determination on their website.Join The Intelligent Investor &amp; saveThis podcast is brought to you by The Intelligent Investor, Australia's premier investment research membership service. Use the code "RASK", to get $100 off your annual membership or get a free 15-day trial (no credit card details required):📈 Click here for a free 15-day trial💸 Click here to join today ($100 off)Trade ASX, US &amp; HK stocks for just $9.50!The Australian Investors Podcast's official broker is SelfWealth. Over 120,000 smart investors use SelfWealth to invest and trade ASX shares, ETFs and global stocks. Rask's Investors Podcast listeners can join today and get $9.50 trades!✅ Click here to join SelfWealthAccess Alan Kohler’s Eureka ReportEureka Report provides investors with information, strategies and general advice to help grow their wealth. Gain exclusive access to CEO’s and fund manager interviews, SuperAdvice for your SMSF &amp; Q&amp;A’s with Alan Kohler. Use the code "RASK10", to get 10% off your annual membership or get a free 15-day trial (no credit card details required), by heading to:🗞 Click here to join today (10% off)📱 Free 15-day trialDISCLAIMER: This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. Because of that, you should consider if the information is appropriate to you and your needs, before acting on it. If you’re confused about what that means or what your needs are, you should always consult a licensed and trusted financial planner. Unfortunately, we cannot guarantee the accuracy of the information in this podcast, including any financial, taxation, and/or legal information. Remember, past performance is not a reliable indicator of future performance. The Rask Group is NOT a qualified tax accountant, financial (tax) adviser, or financial adviser.Full individual disclosures for each guest are available via the show notes page. Owen and The Rask Group Pty Ltd do NOT receive anything for mentioning Super funds, products, shares, bank accounts, etc.Access The Rask Group's Financial Services Guide (FSG): https://www.rask.com.au/fsg Learn more about your ad choices. Visit megaphone.fm/adchoices

Jeremy Curnock Cook is the Managing Director and founder of BioScience Managers, a funds management business specialising in biotechnology investments in Australia and globally. Jeremy joins Owen Rask on The Australian Investors Podcast, alongside Dr Megan Baldwin of Opthea Ltd (ASX: OPT). Dr Baldwin is one of Australia's most experienced biotechnology CEOs and holds a PhD in Medicine.Together, Owen, Megan and Jeremy dive deep into what's included in clinical trials, investing in early, mid and late-stage biotechnology and more.Owen's full investor curriculumTake Owen’s brand new <a href="https://education.rask.com.au/courses/value-investor-program-course-with-equity-mates/" rel="nofollow" target="_blank">Value Investor Program</a>, which gives you all the tools and knowledge you need to invest successfully in companies, including valuation spreadsheets, investing checklists and ASX company case studies. Alternatively, why not take Owen’s FREE investor bootcamp: <a href="http://bit.ly/rask-analyst" rel="nofollow" target="_blank">bit.ly/rask-analyst</a><h3>J.P. Morgan Asset Management</h3>If you want to thank us for putting this show together, please give The Australian Investors Podcast a 5-star review on Apple Podcasts or Spotify - it’s a 5-second task that really helps support the show (and puts a big smile on Owen's face).The Australian Investors Podcast series is proudly supported by J.P. Morgan Asset Management. With over $3.4tn in assets under management globally, J.P. Morgan ETFs push the boundaries of ETF investing to help build stronger, diversified active portfolios. This information is generic in nature and does not constitute as offer or personal financial advice. Investors should seek professional advice, refer to further details, relevant Product Disclosure Statement and Target Market Determination <a href="https://bit.ly/3Vnmf3X" rel="nofollow" target="_blank">on their website</a>.Join The Intelligent Investor &amp; saveThis podcast is brought to you by The Intelligent Investor, Australia's premier investment research membership service. Use the code "RASK", to get $100 off your annual membership or get a free 15-day trial (no credit card details required):📈 <a href="https://www.rask.com.au/ii-trial?utm_source=AIP" rel="nofollow" target="_blank">Click here for a free 15-day trial</a>💸 <a href="https://www.rask.com.au/ii-100?utm_source=AIP" rel="nofollow" target="_blank">Click here to join today ($100 off)</a>Trade ASX, US &amp; HK stocks for just $9.50!The Australian Investors Podcast's official broker is SelfWealth. Over 120,000 smart investors use SelfWealth to invest and trade ASX shares, ETFs and global stocks. Rask's Investors Podcast listeners can join today and get $9.50 trades!✅ <a href="https://bit.ly/sw-pod-rask" rel="nofollow" target="_blank">Click here to join SelfWealth</a>Access Alan Kohler’s Eureka ReportEureka Report provides investors with information, strategies and general advice to help grow their wealth. Gain exclusive access to CEO’s and fund manager interviews, SuperAdvice for your SMSF &amp; Q&amp;A’s with Alan Kohler. Use the code "RASK10", to get 10% off your annual membership or get a free 15-day trial (no credit card details required), by heading to:<a href="https://bit.ly/eurekareport" rel="nofollow" target="_blank">🗞 Click here to join today (10% off)</a><a href="https://bit.ly/ERrask" rel="nofollow" target="_blank">📱 Free 15-day trial</a>DISCLAIMER: This podcast contains general financial information only. That means the information does not take into account your objectives, financial situation, or needs. Because of that, you should consider if the information is appropriate to you and your needs, before acting on it. If you’re confused about what that means or what your needs are, you should always consult a licensed and trusted financial planner. Unfortunately, we cannot guarantee the accuracy of the information in this podcast, including any financial, taxation, and/or legal information. Remember, past performance is not a reliable indicator of future performance. The Rask Group is NOT a qualified tax accountant, financial (tax) adviser, or financial adviser.Full individual disclosures for each guest are available via the show notes page. Owen and The Rask Group Pty Ltd do NOT receive anything for mentioning Super funds, products, shares, bank accounts, etc.Access The Rask Group's Financial Services Guide (FSG): <a href="https://www.rask.com.au/fsg" rel="nofollow" target="_blank">https://www.rask.com.au/fsg</a> Learn more about your ad choices. Visit <a href="https://megaphone.fm/adchoices" rel="nofollow" target="_blank">megaphone.fm/adchoices</a>